|
|
Prezista (Darunavir, TMC114)
| Brand Name: |
Prezista |
| Generic Name: |
darunavir, TMC114 |
| Adult Single Dose: |
Two 300 mg tablets twice daily taken with ritonavir 100 mg twice daily. |
| Food & Liquid Restrictions: |
Take with food. |
| Drug Class: |
PI |
The Basics
- An Overview of Prezista (Darunavir, TMC114) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Darunavir (Prezista) (March 29, 2008)
To read PDF, click here
From AIDS InfoNet
- Patient Information About Prezista (Darunavir, TMC114) (PDF) (February 2008)
From Tibotec Therapeutics
- Prezista (Darunavir, TMC-114) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Prezista (Darunavir, TMC-114) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- An Interview With Cal Cohen, M.D., a Lead Investigator of the Darunavir (TMC114, Prezista) POWER Trials (June 28, 2006)
Dr. Cohen discusses TMC114's uses, adverse effects and other considerations.
- Prezista Approval (June 23, 2006)
From U.S. Food and Drug Administration
News
Research
- Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
- Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
- GRACE Under Pressure (December 2006)
To read PDF, click here
In TAGline, from Treatment Action Group
- 48-Week TMC114 + Ritonavir Data Set New Bar for Efficacy in Triple-Class-Experienced Patients (August 15, 2006)
In XVI International AIDS Conference
- TMC114 Significantly Outperforms Control Protease Inhibitors in Triple-Class-Experienced Patients, Even in Absence of Enfuvirtide (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- New Protease Inhibitor TMC-114: Preliminary 24-Week Late Breaker Results of the Phase II Trial (March/April 2005)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- TMC-114 Sets a New Standard in Salvage Therapy Trials (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group
- Anti-HIV Therapy Update (July 2004)
A quick briefing on tipranavir, TMC-114, capravirine and D-D4FC.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Initial Data on TMC114 in Multiple PI-Experienced Patients (July 16, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
|
|
